Possible derogation for certain pharmaceutical products | REACH restriction on PFOA | Consultation following ECHA’s Executive Director Requests
The Commission has received a request for re-examination of the existing restriction on PFOA and related substances (entry 68 of Annex XVII) in view of including a derogation for the use
of PFOB for the manufacturing of certain pharmaceutical products using pressurised metereddose
inhalers for the treatment of pulmonary diseases.
The companies concerned have informed the Commission that the relevant products contain
low-density phospholipid porous particles as a functional component indispensable for the
efficient delivery of the medicine to the lungs. The manufacture of the porous particles uses
PFOB as a processing aid and unavoidable traces of PFOI are present in the PFOB at around
200 ppm. Whereas PFOB is not restricted, PFOI is a PFOA-related substance covered by the
REACH PFOA restriction under entry 68 of Annex XVII.
More information available on ECHA website
Subscribe to Chemycal PRO to keep track of the regulatory status of PFOA, PFOB and PFOI.